Tenax Therapeutics Q3 2026 net loss widens 6% year over year to $16.7 million
Bitget2026/11/05 12:08- Tenax Therapeutics’ third-quarter 2026 net loss widened 6% year over year to $16.7 million.
- Research and development expenses rose 17% to $12.1 million, while selling, general and administrative expenses fell 12% to $5.7 million year over year.
- Cash and cash equivalents totaled $113.7 million at September 30, 2026, with operations expected to be funded through FY28.
- Enrollment in LEVEL-2 remains temporarily paused while a protocol amendment targets patients more likely to benefit from levosimendan.
- LEVEL missed its primary endpoint; the FDA granted a Type C meeting to discuss levosimendan development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
